LLY
Eli Lilly and Company
LLY has the edge over UFPT overall, supported by stronger fundamentals and stronger valuation.
UFPT
UFP Technologies, Inc.
UFPT's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
UFPT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
UFPT's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
UFPT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $218 | -29% |
| Forward | 28x | $306 | — |
| Fair | 29x | $283 | -7.5% |
| Current | 31x | $306 | — |
| Expensive | 35x | $343 | +12% |
Historical ranges are pointers, not guarantees.
UFPT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
UFPT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for UFPT, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over UFPT on earnings, with stronger typical year-over-year growth.
UFPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.74 | +9.5% |
| Q3 2026 | $9.81 | +14% |
| Q2 2026 | $9.28 | +7.5% |
| Q1 2026 | $8.81 | +7.8% |
| Q4 2025 | $8.78 | +16% |
| Q3 2025 | $8.63 | +23% |
| Q2 2025 | $8.63 | +34% |
| Q1 2025 | $8.17 | +31% |
| Q4 2024 | $7.60 | +30% |
UFPT's earnings per share have climbed steadily: $9.81 over the past year, up 14% from the year before, and higher year over year for nine quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over UFPT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over UFPT on profitability, with a higher operating margin.
UFPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $172.4M | +12% |
| Q2 2026 | $174M | +15% |
| Q1 2026 | $154.2M | +4.1% |
| Q4 2025 | $148.9M | +3.4% |
| Q3 2025 | $154.6M | +6.5% |
| Q2 2025 | $151.2M | +37% |
| Q1 2025 | $148.1M | +41% |
| Q4 2024 | $144.1M | +42% |
UFPT's revenue has grown year over year for 23 quarters in a row: $172M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +0.9 points |
| Q2 2026 | 16% | +0.1 points |
| Q1 2026 | 15% | -0.5 points |
| Q4 2025 | 14% | -1 points |
| Q3 2025 | 15% | -1.9 points |
| Q2 2025 | 16% | -0.2 points |
| Q1 2025 | 16% | +0.4 points |
| Q4 2024 | 15% | +2.9 points |
UFPT's operating margin was 16% last quarter, up 0.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over UFPT on cash flow, with more consistent year-over-year improvement.
UFPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.5M | +7.3% |
| Q2 2026 | $15.6M | -31% |
| Q1 2026 | $3.2M | -71% |
| Q4 2025 | $16.8M | -21% |
| Q3 2025 | $35.9M | +103% |
| Q2 2025 | $22.5M | +151% |
| Q1 2025 | $11M | +23% |
| Q4 2024 | $21.4M | +115% |
UFPT generated $74M in free cash flow over the past year, down 18% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over UFPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
UFPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +18K shares |
| 1 year | +0.3% | +26K shares |
| 3 years | +1.3% | +97K shares |
| 5 years | +2.8% | +209K shares |
| Available history | +3.9% | +290K shares |
UFPT has 8M diluted shares, about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
UFPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.6x | Healthy |
| Q4 2024 | 1.8x | Healthy |
| Q3 2024 | 2.3x | Moderate |
| Q2 2024 | 0.3x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.4x | Very low |
| Q3 2023 | 0.6x | Very low |
UFPT's net debt is about 1.3 years of its operating earnings (EBITDA), up from less than a year a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
UFPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 49.5 | Neutral |
UFPT's weekly RSI is 61 (neutral) and its Stochastic is 50 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
UFPT PE vs Healthcare Sector
| Metric | UFPT | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 21% above |
| PE % | 65 | 29 | 36 pts above |
UFPT has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
UFPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $295.8 | 3.4% above |
| 20 week MA | $284.9 | 7.4% above |
| 50 week MA | $248.9 | 23% above |
| 100 week MA | $237.2 | 29% above |
| 200 week MA | $223.1 | 37% above |
UFPT is in an uptrend: it's above all five of its weekly moving averages, and 37% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over UFPT on returns for 2026, with the stronger performance.
UFPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.7 | $46.2 | -5.2% |
| 2021 | $46.2 | $68.7 | +49% |
| 2022 | $68.7 | $115.5 | +68% |
| 2023 | $115.5 | $172.0 | +49% |
| 2024 | $172.0 | $247.0 | +44% |
| 2025 | $247.0 | $237.2 | -4% |
| 2026 YTD | $237.2 | $305.9 | +29% |
UFPT has finished higher in four of the last six years. It's up 29% so far in 2026.